Literature DB >> 34825931

Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway.

WenJuan Zhang1, YanYan Wang2.   

Abstract

The goal of this study was to investigate the role and mechanism of action of nucleotide oligomerization domain receptor 1 (NOD1) in ovarian cancer. Results showed that the expressions of NOD1 and receptor interacting serine/threonine kinase 2 (RIPK2) were notably upregulated in non-metastatic and metastatic ovarian tumors compared with matched non-tumor tissues, and their expression in metastatic tumor tissues was higher than that in non-metastatic tumors. Overexpression of NOD1 facilitated the expression of proliferation-related proteins (PCNA and Ki67) and proliferation and invasion of ovarian cancer cells. Overexpression of NOD1 promoted NF-κB expression and phosphorylation. Importantly, NOD1 bound with RIPK2, and silencing of RIPK2 partly rescued the promotion of NOD1 to NF-κB expression and its phosphorylation. The promotion of NOD1 to ovarian cancer cell proliferation and invasion was partly reversed by RIPK2 silencing. Results from our in vivo study indicate that overexpression of NOD1 accelerated the growth of ovarian cancer tumors, expression of proliferation-related proteins, and activation of NF-κB. However, silencing of NOD1 suppressed tumor growth. In summary, NOD1 facilitates ovarian cancer progression by activating NF-κB signaling by binding to RIPK2. We suggest a new strategy for the treatment of ovarian cancer.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Invasion; Nucleotide oligomerization domain receptor 1; Ovarian cancer; Proliferation; Receptor interacting serine/threonine kinase 2

Mesh:

Substances:

Year:  2021        PMID: 34825931     DOI: 10.1007/s00418-021-02055-z

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  28 in total

1.  Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors.

Authors:  Ricardo G Correa; Pasha M Khan; Nadav Askari; Dayong Zhai; Motti Gerlic; Brock Brown; Gavin Magnuson; Roberto Spreafico; Salvatore Albani; Eduard Sergienko; Paul W Diaz; Gregory P Roth; John C Reed
Journal:  Chem Biol       Date:  2011-07-29

Review 2.  NOD1 and NOD2: New Functions Linking Endoplasmic Reticulum Stress and Inflammation.

Authors:  Mariana X Byndloss; Arina Marijke Keestra-Gounder; Andreas J Bäumler; Renée M Tsolis
Journal:  DNA Cell Biol       Date:  2016-06-24       Impact factor: 3.311

3.  AGER1 downregulation associates with fibrosis in nonalcoholic steatohepatitis and type 2 diabetes.

Authors:  Ali Dehnad; Weiguo Fan; Joy X Jiang; Sarah R Fish; Yuan Li; Suvarthi Das; Gergely Mozes; Kimberly A Wong; Kristin A Olson; Gregory W Charville; Mohammed Ali; Natalie J Török
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

Review 4.  NOD1 and NOD2: signaling, host defense, and inflammatory disease.

Authors:  Roberta Caruso; Neil Warner; Naohiro Inohara; Gabriel Núñez
Journal:  Immunity       Date:  2014-12-06       Impact factor: 31.745

5.  RIP2 promotes glioma cell growth by regulating TRAF3 and activating the NF‑κB and p38 signaling pathways.

Authors:  Xin Cai; Yongchang Yang; Wengrong Xia; Haibo Kong; Min Wang; Wenliang Fu; Minhui Long; Yuhua Hu; Donggang Xu
Journal:  Oncol Rep       Date:  2018-04-23       Impact factor: 3.906

6.  Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.

Authors:  Brittany M Duggan; Kevin P Foley; Brandyn D Henriksbo; Joseph F Cavallari; Akhilesh K Tamrakar; Jonathan D Schertzer
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

7.  IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway.

Authors:  Leong-Perng Chan; Ling-Feng Wang; Feng-Yu Chiang; Ka-Wo Lee; Po-Lin Kuo; Chia-Hua Liang
Journal:  Oncotarget       Date:  2016-09-20

Review 8.  Ovarian cancer: Current status and strategies for improving therapeutic outcomes.

Authors:  Ashwin Chandra; Cima Pius; Madiha Nabeel; Maya Nair; Jamboor K Vishwanatha; Sarfraz Ahmad; Riyaz Basha
Journal:  Cancer Med       Date:  2019-09-27       Impact factor: 4.452

9.  MicroRNA negatively regulates NF-κB-mediated immune responses by targeting NOD1 in the teleost fish Miichthys miiuy.

Authors:  Qing Chu; Dekun Bi; Weiwei Zheng; Tianjun Xu
Journal:  Sci China Life Sci       Date:  2020-08-17       Impact factor: 6.038

10.  Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity.

Authors:  Thomas B Clarke; Kimberly M Davis; Elena S Lysenko; Alice Y Zhou; Yimin Yu; Jeffrey N Weiser
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

View more
  1 in total

Review 1.  NOD1 and NOD2 Are Potential Therapeutic Targets for Cancer Immunotherapy.

Authors:  Dongjie Wang
Journal:  Comput Intell Neurosci       Date:  2022-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.